Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
rhGH Effects on Intermediate Outcomes in Controlled Trials: Pulmonary Function
This slide presents the summary effects from trials that examined pulmonary function measurements. Pulmonary function measurements showed greater improvement in treated patients than in controls at the conclusion of the studies. However, although the point estimate for percent predicted FEV1 was slightly improved, the difference between treated patients and controls did not reach statistical significance.
The summary effect/mean difference presents the change from baseline as the difference between the means for treated patients and untreated controls.
Keywords: absolute FVC | absolute FEV1 | percent predicted FVC | percent predicted FEV1 | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.